share_log

Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 15% Last Week

Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 15% Last Week

江蘇瑞科生物科技有限公司's (HKG: 2179) 最大的所有者是散戶投資者,他們在上週股價飆升15%後變得更富有
Simply Wall St ·  03/26 20:03

Key Insights

關鍵見解

  • Jiangsu Recbio Technology's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 6 shareholders own 51% of the company
  • Institutional ownership in Jiangsu Recbio Technology is 20%
  • 江蘇瑞科生物科技擁有大量散戶投資者的所有權,這表明關鍵決策受廣大公衆股東的影響
  • 前6名股東擁有公司51%的股份
  • 江蘇瑞科生物科技的機構所有權爲20%

If you want to know who really controls Jiangsu Recbio Technology Co., Ltd. (HKG:2179), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are retail investors with 26% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正控制着江蘇瑞科生物技術有限公司(HKG: 2179),那麼你必須看看其股票登記處的構成。而持有最大份額的群體是擁有26%所有權的散戶投資者。也就是說,如果股票上漲,該集團將受益最大(如果出現低迷,則損失最大)。

As a result, retail investors collectively scored the highest last week as the company hit HK$4.4b market cap following a 15% gain in the stock.

結果,散戶投資者上週集體得分最高,該公司的市值在股價上漲15%後達到44億港元。

In the chart below, we zoom in on the different ownership groups of Jiangsu Recbio Technology.

在下圖中,我們放大了江蘇瑞科生物科技的不同所有權群體。

ownership-breakdown
SEHK:2179 Ownership Breakdown March 27th 2024
SEHK: 2179 所有權明細 2024 年 3 月 27 日

What Does The Institutional Ownership Tell Us About Jiangsu Recbio Technology?

關於江蘇瑞科技,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

We can see that Jiangsu Recbio Technology does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Jiangsu Recbio Technology, (below). Of course, keep in mind that there are other factors to consider, too.

我們可以看到,江蘇瑞科生物科技確實有機構投資者;他們持有該公司很大一部分股票。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎地依賴機構投資者所謂的驗證。他們有時也會弄錯。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看江蘇瑞科生物科技過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SEHK:2179 Earnings and Revenue Growth March 27th 2024
SEHK: 2179 2024 年 3 月 27 日的收益和收入增長

Jiangsu Recbio Technology is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Taizhou Yuangong Technology Partnership (Limited Partnership) with 17% of shares outstanding. For context, the second largest shareholder holds about 8.7% of the shares outstanding, followed by an ownership of 7.8% by the third-largest shareholder.

江蘇瑞科生物科技不歸對沖基金所有。從我們的數據來看,我們可以看到最大股東是台州元工科技合夥企業(有限合夥企業),已發行股份的17%。就背景而言,第二大股東持有約8.7%的已發行股份,其次是第三大股東持有7.8%的所有權。

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們做了進一步的挖掘,發現大股東中有6人約佔登記冊的51%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。有一些分析師對這隻股票的報道,但隨着時間的推移,它仍可能變得更加廣爲人知。

Insider Ownership Of Jiangsu Recbio Technology

江蘇瑞科生物科技的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同國家對內部人士的定義可能略有不同,但董事會成員總是計算在內。公司管理層對董事會的回答,董事會應代表股東的利益。值得注意的是,有時高層管理人員自己也在董事會中。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

We can report that insiders do own shares in Jiangsu Recbio Technology Co., Ltd.. In their own names, insiders own HK$142m worth of stock in the HK$4.4b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

我們可以報告,內部人士確實擁有江蘇瑞科生物科技有限公司的股份。內部人士以自己的名義擁有這家44億港元公司價值1.42億港元的股票。這至少顯示出一定的對齊性。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 26% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散戶投資者在內的公衆擁有該公司26%的股份,因此不容忽視。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Equity Ownership

私募股權所有權

With an ownership of 22%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司擁有22%的所有權,能夠在制定以價值創造爲重點的企業戰略方面發揮作用。有時我們會看到私募股權長期存在,但總的來說,它們的投資期限較短,而且顧名思義,對上市公司的投資並不多。一段時間後,他們可能會考慮出售資金並將其重新部署到其他地方。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 11%, of the Jiangsu Recbio Technology stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

私人公司似乎擁有江蘇瑞科生物科技11%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand Jiangsu Recbio Technology better, we need to consider many other factors. For instance, we've identified 4 warning signs for Jiangsu Recbio Technology (2 make us uncomfortable) that you should be aware of.

擁有公司股份的不同群體總是值得考慮的。但是,要更好地了解江蘇瑞科技,我們需要考慮許多其他因素。例如,我們已經確定了江蘇瑞科生物科技的4個警告信號(2個讓我們感到不舒服),你應該注意這些信號。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但歸根結底,決定這家企業所有者的表現的是未來,而不是過去。因此,我們認爲最好看一下這份免費報告,該報告顯示了分析師是否預測了更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論